ABBREVIATIONS IN TEXT

BACKGROUND
Persistent wet cough, a key feature in a group of paediatric chronic pulmonary disorders, is increasingly appreciated because of the burden it causes to the child, family and healthcare sector. 1, 2 These disorders, dominated by protracted bacterial bronchitis (PBB), chronic suppurative lung disease (CSLD) and bronchiectasis (Box 1), have in common impaired mucociliary clearance and lower airway bacterial infection and inflammation. 3, 4 Haemophilus influenzae (Hi) (usually unencapsulated or non-typeable (NTHi) strains) is consistently the most common bacterial pathogen isolated from the lower airways of children with PBB, CSLD or bronchiectasis, followed less often by Streptococcus pneumoniae (pneumococcus) and Moraxella catarrhalis. 5, 6 Despite childhood immunisation with pneumococcal and encapsulated Hi type b conjugate vaccines, these chronic disorders are commonly seen in paediatric respiratory practice. 5 Acute exacerbations are especially important as not only are they are associated with lower quality of life scores, 1 but the frequency of severe episodes leading to hospitalisation predicts pulmonary decline in children with bronchiectasis. 7 In PBB, recurrent exacerbations (>3/year, termed rPBB) and lower airway Hi infection are associated with future bronchiectasis. 3 Interventions targeting Hi more broadly may be efficacious in reducing exacerbations and improving clinical outcomes. Currently, the only licensed vaccine that may impact upon Hi is the 10-valent pneumococcal-H. influenzae protein D conjugate vaccine (PHiD-CV; Synflorix®, GlaxoSmithKline Biologicals, Belgium). The protein D (PD) component is an outer membrane lipoprotein, which is antigenically conserved, surface located and present in most Hi (encapsulated and NTHi) strains. 8 It is one of three Hi surface proteins (PD, P6 and OMP26) identified as potential vaccine antigens, 9 with PD and P6 showing the most promise. Vaccine-induced anti-PD antibodies are associated with protective efficacy against Hi infection in middle ear and pulmonary clearance in rat disease models. 10 To date, no studies have evaluated PD-based vaccines in children with rPBB, CSLD or bronchiectasis.
We aimed to determine the clinical efficacy, immune response, impact on nasopharyngeal carriage of Hi and safety of two doses of PHiD-CV in children with rPBB, CSLD or bronchiectasis. We tested the primary hypothesis that amongst children aged 18-months to <18-years with rPBB, CSLD or bronchiectasis, PHiD-CV reduces the incidence of respiratory exacerbations in the 12-months following two doses of vaccine compared to children who received a control conjugate vaccine (quadrivalent meningococcal ACYW 135, MenACYW 135 ; Menactra, Sanofi Pasteur, Lyon).
RESULTS
Study cohort
Between December 2012 and August 2015, 975 children were screened and 75 enrolled (63 onto the full clinical protocol and 12 onto the immunology only protocol) ( Figure 1 ). One child was a screen failure (clinical protocol) and thus 74 children were randomised. A participant on the clinical protocol was unblinded following dose-2 at the request of the ethics committee and following discussion with the Data Safety Monitoring Committee (DSMC) . This was after a severe local reaction to the 23-valent pneumococcal polysaccharide vaccine (PPV23), which was deemed unrelated to the study. However, this child was not included in the clinical analyses. Six children were withdrawn from the study at parental request due to family commitments over the 14-months of the study and two were lost to follow-up ( Figure 1 ).
The mean age of the 74 children was 6.8 (standard deviation 3.7) years, 56.8% were male and at baseline the overall characteristics between the PHiD-CV and control vaccine groups (Table 1) were similar. Importantly, baseline prior pneumococcal vaccination history was comparable between the groups, in particular the proportion of those who had had at least three doses of a pneumococcal conjugate vaccine (PCV) and at least 1 dose of PPV23, as well as the median time in months since the last dose of either vaccine (Table 1) .
Clinical outcomes
Amongst the 61 children included in the clinical analyses, the overall incidence density of acute exacerbations following dose 2 was 4.4 episodes per 100 child-weeks at risk (95% confidence interval (CI) 3.7, 5.2); the incidence density ratio (IDR) between the groups was 0.92 (95%CI 0.68, 1.32) ( three of the seven events in the control group occurred in one child who also had severe cerebral palsy.
Immunological outcomes
The complete dataset for saliva and serum antibody titres at each study time-point by vaccine group are presented in Supplementary Tables 1-5 . Table 1 )
Salivary antibodies to H. influenzae and pneumococcal proteins (Supp
At baseline, there were no between-group differences in anti-PD saliva antibodies (p=0.238; Supp Table 1 ). However, between-group differences were observed for IgG antibodies to Hi proteins P6
IgG and P26 IgG and for IgG antibodies to pneumococcal proteins PspA2 IgG and Ply IgG with higher titres observed in the MenACYW 135 vaccine group for all four proteins at baseline.
While no anti-PD saliva IgA response was observed at any time-point in the PHiD-CV group, anti-PD saliva IgG increased following both doses of vaccine and significant differences between the PHiD-CV and MenACYW 135 groups were sustained to 12-months following the second dose ( Figure 2 ). In contrast, no saliva IgA or IgG responses were observed to Hi proteins P4, P6 and P26 or to any of the pneumococcal proteins. Table 2 )
Salivary antibodies to pneumococcal polysaccharides (Supp
At baseline significant between-group differences were observed for saliva anti-pneumococcal 
Similarly, at
12-months post-dose 2, there were no differences between groups for serotypes 1, 5, 6B, 7F, 9V, 19F
and 23F for IgA, and 6B, 9V and 23F IgG antibodies respectively. Table 3 )
Serum antibodies to H. influenzae and pneumococcal proteins (Supp
There were no baseline between-group differences in Hi and pneumococcal serum antibody geometric meant tires (GMT; Supp Table 3 ). Increases in serum anti-PD IgA were observed in the PHiD-CV group following the second dose and serum anti-PD IgG increased following the first dose ( Figure 3 ).
GMTs for anti-PD IgA and IgG antibodies were higher in the PHiD-CV than MenACYW 135 group at the 12-month post dose 2 time-point. There were no changes in serum IgA and IgG antibodies to P4, P6 and P26 nor to any of the pneumococcal proteins. Table 4 Table 5 Interpreting culture data was complicated by the high antibiotic use throughout the study, particularly azithromycin ( Figure 4 ) and subsequently no further culture analyses were undertaken.
Serum antibodies to pneumococcal polysaccharides (Supp
Microbiological outcomes (Supp
Of all swabs collected over the study period (n=320), Hi was identified in just 25, including four (16%) that were beta-lactamase positive. Overall, 18 (72%) Hi isolates were hpd positive and 19 (76%) were fucP gene positive differentiating them from the commensal organism, H. haemolyticus. However, no differences in these characteristics existed between vaccine groups.
Of the 51 culture positive swabs for pneumococci (n=18 in PHiD-CV group and n=33 in MenACYW 135 group), serotypes 19F and 15B (7/51 (13.7%) for each serotype respectively) were the most common overall. While they were also the most common serotypes identified in the 
Safety outcomes
Parent-completed diary cards were not available for three vaccine doses (one in the PHiD-CV group following dose 1 and one each in the MenACYW 135 group after doses 1 and 2). The proportions of children reporting any local reaction in the 7-days post each vaccine dose were higher in the PHiD-CV (94% and 91%) than the MenACYW 135 group (56% and 50%) for each dose respectively ( Figure   6 ). There were no between-group differences in the 7-day general solicited and 30-day unsolicited symptoms. Of the local symptoms, pain was the most common (PHiD-CV 28/34 (82%) and 29/32 (91%); MenACYW 135 16/36 (44%) and (14/36 (39%) following the first and second doses respectively), most of which was mild and self-limiting. Pain was the only symptom to increase in severity following the second vaccine dose and only occurred in the PHiD-CV group (1 (3%) and 5 (16%) after doses 1 and 2 respectively reported severe pain). None sought medical attention for these severe pain events.
Nineteen serious adverse events (SAEs) were reported over the course of the study (5 PHiD-CV group; 14 MenACYW 135 group). None were considered causally related to study vaccines. Of these SAEs, eight were for exacerbations of the child"s pre-existing illness (see above).
DISCUSSION
Our study provides the first data on PHiD-CV in children with rPBB, CSLD and bronchiectasis.
Despite not achieving the required sample size, and the consequent fragility of the data, we observed that compared with control children, those receiving PHiD-CV had fewer fortnights with respiratory symptoms and antibiotic courses although the difference was not statistically significant. Further, there were fewer hospitalised exacerbations in the PHiD-CV group, however the actual number of events and children were small. PHiD-CV also induced both serum and salivary anti-PD antibodies and was generally well-tolerated, despite higher proportions of recipients than controls experiencing local reactions following both vaccine doses.
There are no comparable data with which to compare our findings. A Cochrane Review of six randomised controlled trials (RCTs) involving an oral, whole cell NTHi vaccine in 557 adults with either chronic obstructive pulmonary disease or chronic bronchitis found no effect on exacerbations or hospitalisations. 11 However, a subgroup analysis of the largest trial in the review, which was restricted to 91 subjects aged <65-years, reported efficacy (p<0.001) against all major endpoints, including reductions of 54% in exacerbations, 22% in antibiotic courses and 62% in corticosteroid use. 12 Notwithstanding the limitations associated with post-hoc analyses and the different patient populations, as a potential "proof of principle" the point estimate for reduced antibiotic use is similar to the 19% we observed in our study. Given worldwide concerns over increasing antibiotic resistance, 13 our study provides promising preliminary data to suggest that PHiD-CV could decrease antibiotic use in children with chronic pulmonary infections.
We observed a reduction in fortnights with respiratory symptoms following both doses of the PHiD-CV vaccine. The symptoms we recorded are common to both upper and lower respiratory infections and hence may include milder viral illnesses. We have not yet tested for viruses, but interactions between both Hi and pneumococci may be important. Hi colonisation of the airways alters immune responses to subsequent viral infections, potentially increasing susceptibility to exacerbations.
14 Further, there is growing evidence viruses predispose to pneumococcal infection by disrupting epithelial barriers and altering innate and adaptive immune responses, and that these actions can be ameliorated by pneumococcal vaccination. 15 A caveat of finding a reduction in fortnights with respiratory symptoms is that the duration and consistency of symptoms were not measured and hence whether it was one or more events within and across fortnights was not accounted for in the analysis.
The serum and salivary immune responses to vaccination in the study children suggest that except for saliva IgA, two doses of PHiD-CV induce significant boosting to anti-PD antibody and to most vaccine-type pneumococcal polysaccharide antibodies that persists for 12-months following the second vaccine dose. IgA antibodies observed in saliva are indicative of stimulation of a mucosal immune response following vaccination, which may also be reflected at other mucosal sites, including the upper airways. 16 Importantly, in this highly vaccinated population, there was no indication of hyporesponsiveness to the common polysaccharide antigens, although the limited sample size precluded analyses by prior vaccination status. Data in children and adults with bronchiectasis suggest systemic deficiencies in IFN-ɣ production, 17, 18 especially in cytotoxic Tlymphocytes and natural killer cells. In children, this systemic deficiency correlated with increased lower airway inflammation 17 and importantly, the reduced IFN-ɣ production to Hi can be reversed following PHiD-CV vaccination. 19 These data, together with the systemic and mucosal antibody responses observed in our study, and the preliminary clinical findings, suggest vaccination against Hi may be an important adjuvant to managing children with rPBB, CSLD and bronchiectasis.
The NPS culture data in this study are difficult to interpret given the low proportion of positive specimens, and the frequent use of antibiotics during the study. 20 At baseline, only 8.1% of NPS were culture positive for Hi and 18.9% were pneumococcus culture positive. This compares with positive NPS culture results of 30.6% and 29.5% for Hi and pneumococci respectively in Queensland children undergoing bronchoscopy for chronic cough during the same time period. 21 The difference between the two studies, despite a similar distribution of children with PBB (not all recurrent), CSLD and bronchiectasis and the same laboratory performing the microbiology testing, is likely explained by children in the bronchoscopy study being newly-diagnosed with these chronic pulmonary infections, whereas children in our study were already receiving treatment for their disease. NPS collected while a child is anaesthetised for bronchoscopy may be of better specimen quality for culture. Azithromycin is used commonly in this patient population 22 and in the current study over 40% of participants had received the antibiotic at least once during the trial. Azithromycin has long-term effects on carriage, 22, 23 lasting several months after ceasing therapy, and the small sample size and number of positive NPS cultures precluded differentiating trends in carriage between vaccine and antibiotic effects.
PHiD-CV was generally well tolerated with most adverse events being mild, self-limiting and within the ranges reported in other studies. 24 However, a higher proportion of children in the PHiD-CV group reported pain following both doses of vaccine compared to the MenACYW 135 group and it was the only reaction that increased in severity following the second vaccine dose. The most plausible explanation for this finding is that PHiD-CV contains an alum adjuvant, as do other PCVs (PCV7 and PCV13), and PPV23, while the MenACYW 135 vaccine used in this study does not. Increasing reactogenicity with cumulative exposure to alum adjuvants in several vaccines, as experienced by children in the study, has been reported elsewhere and may reflect both local tissue damage and systemic inflammation induced by innate immune receptor activation. 25 The major limitation of our study is the premature termination of the study, resulting in the small sample size and inability to adequately address the primary endpoint and perform important subgroup analyses of the data, such as further exploration of potential baseline differences in exposure to household tobacco smoke. The reason for the imbalance is unknown, but is likely a reflection of the small numbers in each group (two children exposed in the PHiD-CV group and seven in the MenACYW 135 group). The challenges of recruitment included confirming eligibility criteria (particularly exacerbation history), the reluctance of parents to subject their child to further, non-essential medical intervention (including blood tests and further clinical studies) and competing studies in the same patient population. However, the trial"s experience provides valuable information for the design and implementation of further studies. Secondly, we did not have a group that received a PCV only vaccine and hence there is uncertainty over whether the clinical outcomes we observed may be due to effects on pneumococcal infection, particularly given the boosting of pneumococcal antibodies. Further exploration of this possibility is also limited by the low proportion of pneumococcal culture positive swabs. Finally, approximately 40% of participants received azithromycin during the conduct of the study and given its prolonged effect upon the airways and the inability to model the data, we cannot definitively conclude that the effects we observed were not due to azithromycin. 26 However, the number of children receiving azithromycin and the duration of the treatment courses was similar between the two study groups.
CONCLUSION
Our study provides the first clinical and immunological data for a Hi vaccine, including one that also addresses pneumococcal infection, in children with rPBB, CSLD and bronchiectasis. It raises the possibility of important clinical effects warranting further investigation in this important group of children with chronic pulmonary disorders. However, the failure to achieve the required sample size and the lack of any statistically significant differences in our primary and secondary clinical outcomes means that our findings are instead hypothesis generating and require cautious interpretation.
Consequently, these data will inform larger studies in a broader patient population, including adults, and serve to encourage future trials of candidate Hi vaccines.
METHODS
Design
We conducted a multi-centre, parallel group, double-blind, RCT. The study protocol was published previously. 27 Briefly, children aged 18-months to <18-years with rPPB, CSLD or bronchiectasis were recruited from specialist respiratory clinics in tertiary paediatric hospitals in Brisbane, Perth, Sydney 
Published protocol changes
The original protocol limited the upper age of participants to <15-years. 27 Recruitment difficulties and limited funding meant the recruitment age was lifted to <18-years, another study site ( 
Randomisation and masking
An independent biostatistician prepared the randomisation code using a permuted blocking design (block size of 4) to maintain group balance. 27 Randomisation was stratified by site (n=4), age (<6-years and ≥6-years), and rPBB vs CSLD/bronchiectasis. Allocation concealment was achieved by consecutively numbered opaque sealed envelopes. Since the vaccines differed in colour and packaging, preparation and delivery was performed by nurses independent of the study and without blinded staff present. Blinding of investigators, study staff and participants was maintained until children on the clinical protocol had completed follow-up and the clinical data had been cleaned and locked and blinded analyses of the clinical data had been completed. With the approval of the DSMC and the coordinating ethics committee, unblinding was then performed with the exception of ongoing participants in the immunology only cohort. The laboratories performing all immunology and microbiology procedures remained blinded for the complete duration of the study.
Specimen collection and laboratory procedures
In children enrolled in the full clinical protocol, serum, saliva and NPS were collected at enrolment and at 2-months post-vaccine dose 1, and then at 1, 6 and 12-months following the second vaccine dose. These specimens were also collected at enrollment and 1-month post-vaccine dose 2, with optional collection at 12-months post-dose 2 from children on the immunology protocol. Although parents and/or the child could refuse specimen collection, extra emphasis was placed on ensuring at least the baseline and 1-month post-dose 2 specimens were obtained. Specimens were processed using published procedures 27 and stored locally at participating centres at -80 o C before being transported frozen to the research laboratories.
Outcomes
The primary clinical outcome was the incidence of respiratory exacerbations in the 12-months following the second vaccine dose. Child-time at risk of an exacerbation commenced 14-days following receipt of the second vaccine dose and the denominator for calculating incidence densities also excluded the time when the child had an exacerbation. At least 14-days following the child"s cough returning to baseline was required before a subsequent increase in symptoms was classified as a new exacerbation. The secondary clinical outcomes were the antibiotic courses prescribed for cough (courses <14-days or <28-days) and the frequency of fortnights when a parent/guardian reported respiratory symptoms during child-time at risk. Respiratory symptoms collected by nurses interviewing parents/carers at fortnightly surveillance contacts included any cough (ie wet or dry), parent-reported fever (+thermometer recording), nasal discharge/congestion, sore throat, wheeze, and difficulty breathing.
Parents were educated on these symptoms at enrolment. As part of SAE surveillance, hospitalised
exacerbations were recorded for all participants.
The primary immunological outcomes were serum and saliva IgA and IgG antibody titres to PD at 1- 
Sample size
Prospective data collected in Brisbane children with bronchiectasis attending a specialist respiratory clinic indicated a mean annual incidence of 2.1 (standard deviation 1.046) exacerbations requiring hospital clinic attendance or hospitalisation (Chang, unpublished data) . Based on these data and results from the POET study (30% reduction in otitis media), 30 our trial was powered to detect a 30% reduction from 2.1 to 1.47 exacerbations in the 12-months following the second vaccine dose.
Assuming a Poisson distribution, 93 children per group would have provided 90% power (α=0.05, 2-sided) to detect a 30% reduction in exacerbations in the PHiD-CV group and 80% power to detect a 25% reduction. Assuming a 10% loss to follow-up, we aimed to recruit 206 children (103 per group).
Differences <20% were considered unlikely to change clinical practice without additional supporting evidence. However, given recruitment difficulties and exhaustion of grant funds, the study was stopped after enrolling 75 children.
Analysis
Demographic data were tabulated and expressed as proportions and/or means or medians of the selected characteristics by vaccine group with the corresponding 95%CI or interquartile ranges. The T-test for comparisons of means, Wilcoxon signed-rank test for medians and χ2 tests for comparison of proportions assessed between-group differences.
Poisson regression was employed to calculate the primary endpoint and antibiotic use rate ratios and CIs, following assessment of distributional assumptions and using robust standard errors. The primary analysis compared the incidence density of respiratory exacerbations between the two groups with child-time at risk commencing 14-days following the second vaccine dose. As children are not at risk of an event while they are experiencing an event, the total duration of each event (in days) was subtracted from the total time of observation to obtain the child-time at risk denominator used in calculating incidence density rates. Absolute risk differences and IDRs were calculated to compare exacerbation incidence in the PHiD-CV and control groups respectively and presented with their 95%
CIs. The same comparisons were performed for courses of antibiotics. Fortnights with respiratory symptoms were counted on the basis of a "yes" or "no" parent response to whether or not the child had had any symptoms in that fortnight; individual symptoms and duration of symptoms within and between fortnights were not analysed for this paper. A log-binomial model, incorporating a robust standard error and Bernoulli random variable was employed to calculate rate ratios for respiratory symptom fortnights. All analyses were performed on an intention-to-treat basis.
Group-specific serum and saliva antibody responses to Hi and pneumococcal proteins and pneumococcal polysaccharide antigens were compared at each sampling time-point. Analyses were first performed using non-parametric methods (Wilcoxin signed-rank test). Data were then logtransformed to assess normality and if normality assumptions were met, T-tests were used to compare transformed data, otherwise non-parametric methods were employed. Log-transformed data were then 
